Our screening procedure was robust as a subset of the highly ranked genes (BAX, BIM, BAP1, and SPRED2) had previously been correlated to either CML progression, imatinib resistance, or resistance to alternative therapies in different cancer types.24, 34, 35, 36, 37. Here, BCL2L11 is linked to cancer.